Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role

Simple item page
dc.contributor.authorPelidou, S. H.en
dc.contributor.authorZou, L. P.en
dc.contributor.authorDeretzi, G.en
dc.contributor.authorOniding, C.en
dc.contributor.authorMix, E.en
dc.contributor.authorZhu, J.en
dc.date.accessioned2015-11-24T19:19:16Z
dc.date.available2015-11-24T19:19:16Z
dc.identifier.issn0014-4886-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21946
dc.rightsDefault Licence-
dc.subjectAcute Diseaseen
dc.subjectAdministration, Intranasalen
dc.subjectAnimalsen
dc.subjectCells, Cultureden
dc.subjectChronic Diseaseen
dc.subjectDisease Progressionen
dc.subjectDose-Response Relationship, Drugen
dc.subjectImmunohistochemistryen
dc.subjectInterleukin-17/administration & dosage/*immunologyen
dc.subjectLeukocytes, Mononuclear/cytology/drug effectsen
dc.subjectLymphocyte Activation/drug effects/immunologyen
dc.subjectMaleen
dc.subjectMiceen
dc.subjectMyelin P2 Protein/immunologyen
dc.subjectNeuritis, Autoimmune, Experimental/*immunology/pathologyen
dc.subjectPeptide Fragments/immunologyen
dc.subjectRatsen
dc.subjectRats, Inbred Lewen
dc.subjectRecombinant Proteins/administration & dosage/immunology/therapeutic useen
dc.subjectSciatic Nerve/drug effects/pathologyen
dc.subjectTumor Necrosis Factor-alpha/metabolismen
dc.titleEnhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory roleen
heal.abstractExperimental autoimmune neuritis (EAN) is a CD4(+) T-cell-mediated demyelinating disease of the peripheral nervous system (PNS). We examined the effect of recombinant mouse interleukin 17 (rmIL-17) on chronic EAN induced in Lewis rats by inoculation of P2 57-81 peptide in Freund's complete adjuvant. Animals were treated nasally for 6 days with either 0.1 or 0.9 microg/rat/day rmIL-17 from the onset of neurological signs, i.e., days 9 to 14 postimmunization (p.i.). Prolonged follow-up demonstrated a chronic course in control and rmIL-17-treated rats. Treated rats had more severe disease initially (days 18-36 p.i.) with a stronger enhancing effect observed with the higher rmIL-17 dose. At day 19 rmIL-17-treated rats showed increased infiltration of inflammatory cells into the sciatic nerve, more severe demyelination, augmented proliferation of regional lymph node cells, and increased serum levels of tumor necrosis factor-alpha. After the initial phase of disease enhancement the IL-17-treated EAN rats improved gradually and ultimately recovered completely, whereas the control EAN rats remained affected until the end of the observation (day 120 p.i.). The lower dose of rmIL-17 induced an earlier recovery from clinical deficits than the higher one. The results indicate that IL-17 plays an immunoregulatory role in chronic EAN which could have implications for immunomodulatory treatments of chronic autoimmune disease of the PNS.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1006/exnr.2000.7357-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10785455-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0014488600973576/1-s2.0-S0014488600973576-main.pdf?_tid=bcff35d1260c14239710b3ce2f6f4eec&acdnat=1332844618_80dd581d1d066ba347bdc6937731c840-
heal.journalNameExp Neurolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.74 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ